Pure Biologics S.A. (WSE:PUR)
Poland · Delayed Price · Currency is PLN 2.205
+0.025 (1.15%)
Jun 16, 2026, 3:00 PM CET
Pure Biologics Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | - | 0.66 | 0.25 | |
Revenue Growth (YoY) | - | - | - | - | 160.63% | -55.59% |
Cost of Revenue | 0.19 | 0.03 | 0.05 | 0.06 | 6.07 | 4.28 |
Gross Profit | -0.19 | -0.03 | -0.05 | -0.06 | -5.41 | -4.03 |
Selling, General & Admin | 6.45 | 5.8 | 14.92 | 18.26 | 28.71 | 20.69 |
Other Operating Expenses | -0.12 | -0.25 | -2.89 | -10.99 | -11.93 | -17.15 |
Operating Expenses | 6.44 | 5.71 | 12.34 | 7.48 | 19.28 | 6.46 |
Operating Income | -6.64 | -5.74 | -12.38 | -7.54 | -24.68 | -10.49 |
Interest Expense | -2.55 | -2.19 | -1.33 | -0.86 | -0.33 | -0.23 |
Interest & Investment Income | 0.01 | 0.01 | - | 0.28 | 0.2 | 0.09 |
Currency Exchange Gain (Loss) | 0.09 | 0.09 | 0.52 | -0.41 | -0.02 | -0.06 |
Other Non Operating Income (Expenses) | -0.01 | -0.01 | 0 | -0 | - | - |
EBT Excluding Unusual Items | -9.1 | -7.83 | -13.19 | -8.53 | -24.83 | -10.69 |
Gain (Loss) on Sale of Investments | - | - | - | -0.02 | -0.82 | -1.09 |
Gain (Loss) on Sale of Assets | - | - | - | 0.01 | 0.05 | 0.01 |
Other Unusual Items | - | - | - | -1.62 | - | - |
Pretax Income | -9.1 | -7.83 | -13.19 | -10.15 | -25.6 | -11.77 |
Earnings From Continuing Operations | -9.1 | -7.83 | -13.19 | -10.15 | -25.6 | -11.77 |
Earnings From Discontinued Operations | -1.63 | -1.99 | -6.25 | -25.55 | - | - |
Net Income | -10.73 | -9.82 | -19.44 | -35.69 | -25.6 | -11.77 |
Net Income to Common | -10.73 | -9.82 | -19.44 | -35.69 | -25.6 | -11.77 |
Shares Outstanding (Basic) | 7 | 5 | 3 | 3 | 2 | 2 |
Shares Outstanding (Diluted) | 7 | 5 | 3 | 3 | 2 | 2 |
Shares Change (YoY) | 108.92% | 41.27% | 9.27% | 41.50% | 1.48% | 34.29% |
EPS (Basic) | -1.48 | -1.99 | -5.58 | -11.19 | -11.36 | -5.30 |
EPS (Diluted) | -1.48 | -1.99 | -5.58 | -11.19 | -11.36 | -5.30 |
Free Cash Flow | -8.63 | -6.25 | -10.83 | -23.44 | -23.15 | -24.71 |
Free Cash Flow Per Share | -1.20 | -1.27 | -3.11 | -7.35 | -10.27 | -11.12 |
Operating Margin | - | - | - | - | -3728.40% | -4129.13% |
Profit Margin | - | - | - | - | -3867.52% | -4631.89% |
Free Cash Flow Margin | - | - | - | - | -3496.22% | -9727.56% |
EBITDA | -6.54 | -5.62 | -12.24 | -7.47 | -22.46 | -7.84 |
D&A For EBITDA | 0.09 | 0.12 | 0.14 | 0.07 | 2.23 | 2.65 |
EBIT | -6.64 | -5.74 | -12.38 | -7.54 | -24.68 | -10.49 |